Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / May / The Counterfeit COVID-19 Crisis
Business & Regulation Trends & Forecasts Supply Chain Quality & Compliance Small Molecules Supply Chain Regulation & Standards Small Molecules

The Counterfeit COVID-19 Crisis

How fakers are taking advantage of the pandemic

By Stephanie Vine 05/25/2020 1 min read

Share

COVID 19 has brought out the very best of the industry. Pharma companies seem to be moving faster – and collaborating more – than ever before. But every light creates a shadow. As pharma companies go to work, their arch-nemesis ups its game. Yes, counterfeiters are preying on a worried global population.

Counterfeit pharmaceuticals are a traditionally tricky problem to address. Manufacturers try to deter counterfeiters through clever formulation and packaging strategies, but the counterfeit pharmaceutical market is temptingly lucrative. For example, $1,000 invested in falsified drugs can result in profits of $500,000 – compared with profits of around $20,000 dollars for heroin trafficking (1). The panic created by COVID-19 presents a huge opportunity for criminals as people flock online for medicines and personal protective equipment.

Interpol’s annual Operation Pangea took place in March – and those involved noted a theme. Compared with 2018, there was an increase of around 18 percent in seizures of unauthorized antiviral medication, and an increase of more than 100 percent in seizures of unauthorized chloroquine (2). In addition, the operation discovered 2,000 online links advertising COVID-19 related items, and seized more than 34,000 counterfeit and substandard masks, as well as medicines advertised as “corona sprays, “coronavirus packages” and “coronavirus medicines.”

High-profile individuals touting the benefits of certain medicines have compounded the issue; online demand for hydroxychloroquine surged 1000 percent after it was endorsed by Elon Musk and Donald Trump, as users explored the sites of Amazon, eBay, Walmart and other popular sites for the drug (3).

Panicked consumers are not the only party being exploited by criminal gangs – companies are also at risk. Interpol recently described, in detail, how one company became victim to an elaborate scam involving an order of masks (4). The moral of the story: we must all be super vigilant.

Just as pharma companies are stepping up to develop new COVID-19 treatments, we are also likely to see more partnerships aimed at stemming counterfeits. In the USA, changes are already afoot, with 3M, Amazon and Pfizer collaborating with US Immigration and Customs Enforcement to stem the flood of counterfeit COVID-19 products. Even during a pandemic, counterfeiters do not rest – and neither should efforts to fight them.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Sanofi, “Falsified Medicines: a Criminal Activity that Endangers the Life of Patients,” (2018). Available at https://bit.ly/2SK83mS.
  2. Interpol, “Global operation sees a rise in fake medical products related to COVID-19,” (2020). Available at https://bit.ly/3fC9QnU.
  3. Interpol, “Unmasked: International COVID-19 fraud exposed,” (2020). Available at https://bit.ly/35By5hp.
  4. M Liu et al., “Internet Searches for Unproven COVID-19 Therapies in the United States,” JAMA Intern Med (2020).

About the Author(s)

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.